Efficacy of different photoprotection strategies in preventing actinic keratosis new lesions after photodynamic therapy. The ATHENA study: a two-center, randomized, prospective, assessor-blinded pragmatic trial

References

• Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42:S4-S7
   PubMed Web of Science ®Google Scholar
• Kennedy C, Willemze R, de Gruijl FR, et al. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Invest Dermatol 2003;120:1087-93
   PubMed Web of Science ®Google Scholar
• Flohil SC, Van Der Leest RJ, Dowlatshahi EA, et al. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam study. J Invest Dermatol 2013;133:1971-8
   PubMed Web of Science ®Google Scholar
• Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42:S8-S10
   PubMed Web of Science ®Google Scholar
• Ratushny V, Gober MD, Hick R, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 2012;122:464-72
   PubMed Web of Science ®Google Scholar
• Mittelbronn MA, Mullins DL, Ramos-Caro FA, et al. Frequency of pre‐existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998;37:677-81
   PubMed Web of Science ®Google Scholar
• Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 1953;6:963-8
   PubMed Web of Science ®Google Scholar
• Vatve M, Ortonne JP, Birch-Machin MA, et al. Management of field change in actinic keratosis. Br J Dermatol 2007;157(s2):21-4
   PubMed Web of Science ®Google Scholar
• Szeimiesa RM, Karrera S, Radakovic-Fijanb S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:258-62
   PubMed Web of Science ®Google Scholar
• Wiegell SR, Wulf HC, Szeimies RM, et al. Daylight photodynamic therapy for actinic keratosis: an international consensus. J Eur Acad Dermatol Venereol 2012;26:673-9
   PubMed Web of Science ®Google Scholar
• Werner RN, Stockfleth E, Connolly SM, et al. Evidence‐and consensus‐based (S3) guidelines for the Treatment of Actinic Keratosis–International League of Dermatological Societies in cooperation with the European Dermatology Forum–Short version. J Eur Acad Dermatol Venereol 2015;29:2069-79
   PubMed Web of Science ®Google Scholar
• De Berker D, McGregor JM, Hughes BR, et al. Guidelines for the management of actinic keratoses. Br J Dermatol 2007;156:222-30
   PubMed Web of Science ®Google Scholar
• Babino G, Diluvio L, Bianchi L, et al. Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study. Curr Med Res Opin 2016;32:1345-9
   PubMed Web of Science ®Google Scholar
• Puviani M, Galloni C, Marchetti S, et al. Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3-month trial. Curr Med Res Opin 2017;33:1255-9
   PubMed Web of Science ®Google Scholar
• Garofalo V, Ventura A, Mazzilli S, et al. Treatment of multiple actinic keratosis and field of cancerization with topical piroxicam 0.8% and sunscreen 50+ in organ transplant recipients: a series of 10 cases. Case Rep Dermatol 2017;9:211-16
   PubMed Web of Science ®Google Scholar
• Scotti E, Deledda S, Milani M. Efficacy of a film-forming medical device containing piroxicam and sun filters in the treatment of multiple actinic keratosis lesions in a subject with a history of kaposi sarcoma. Case Rep Dermatol 2016;8:254-61
   PubMed Web of Science ®Google Scholar
• Brogden RN, Heel RC, Speight TM, et al. Piroxicam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1981;22:165-87
   PubMed Web of Science ®Google Scholar
• Mirshafiey A, Vaezzadeh F, Khorramizadeh MR, et al. Effect of piroxicam on matrix metalloproteinase 2 and apoptosis. Int J Tissue React 2004;26:1-7
   PubMedGoogle Scholar
• Mazumder MK, Bhattacharya P, Borah A. Inhibition of matrix metalloproteinase-2 and 9 by Piroxicam confer neuroprotection in cerebral ischemia: an in silico evaluation of the hypothesis. Med Hypoth 2014;83:697-701
   PubMed Web of Science ®Google Scholar
• Cini R, Pogni R, Basosi R, et al. Oxygen radical scavenger activity, EPR, NMR, molecular mechanics and extended-Hückel molecular orbital investigation of the bis (piroxicam) copper (II) complex. Metal-based Drugs 1995;2:43-56
   PubMedGoogle Scholar
• General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent 2014;81:14
   PubMedGoogle Scholar
• Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix®) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatol Treat 2003;14:99-106
   PubMedGoogle Scholar
• Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator‐blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol 2015;29:2342-8
   PubMed Web of Science ®Google Scholar
• Elbenschutz L, Silipo V, De Simone P, et al. A 9-month, randomized, assessor-blinded, parallel-group study to evaluate clinical effects of film-forming medical devices containing photolyase and sun filters in the treatment of field cancerization compared with sunscreen in patients after successful photodynamic therapy for actinic keratosis. Br J Derm 2016;175(6):1391–1393
   PubMed Web of Science ®Google Scholar
• Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19:723-9
   PubMed Web of Science ®Google Scholar
• Brogden RN, Heel RC, Speight TM, et al. Piroxicam. Drugs 1984;28:292-323
   PubMed Web of Science ®Google Scholar
• Blanco FJ, Guitian R, Moreno J, et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol 1999;26:1366-73
   PubMed Web of Science ®Google Scholar
• Ahrens D, Koch AE, Pope RM, et al. Expression of matrix metalloproteinase 9 (96‐kd gelatinase B) in human rheumatoid arthritis. Arthrit Rheum 1996;39:1576-87
   PubMed Web of Science ®Google Scholar
• Jetter N, Chandan N, Wang S, et al. Field cancerization therapies for management of actinic keratosis: a narrative review. Am J Clin Dermatol 2018;19:543-557
   PubMed Web of Science ®Google Scholar
• Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329:1147-51
   PubMed Web of Science ®Google Scholar
• Zane C, Facchinetti E, Rossi MT, et al. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol 2014;170:1143-50
   PubMed Web of Science ®Google Scholar
• Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol 2014;171:1164-71
   PubMed Web of Science ®Google Scholar
• Wiegell SR, Fabricius S, Gniadecka M, et al. Daylight‐mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study. Br J Dermatol 2012;166:1327-32
   PubMed Web of Science ®Google Scholar
• Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol 2014;171:1164-71
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Piccioni A, Neri L, et al. Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra‐patient, prospective, comparison study in Italy. J Eur Acad Dermatol Venereol 2015;29:1926-32
   PubMed Web of Science ®Google Scholar
• Morton CA, Wulf HC, Szeimies RM, et al. Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus. J Eur Acad Dermatol Venereol 2015;29:1718-23
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008;18:651-9
   PubMed Web of Science ®Google Scholar